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AbstrAct
The dura is a rare site of involvement by marginal zone lymphoma (MZL) and 
the biology of dural MZL is not well understood. We performed genome-wide DNA 
copy number and targeted mutational analysis of 14 dural MZL to determine the 
genetic landscape of this entity. Monoallelic and biallelic inactivation of TNFAIP3 
by mutation (n=5) or loss (n=1) was observed in 6/9 (67%) dural MZL exhibiting 
plasmacytic differentiation, including 3 IgG4+ cases. In contrast, activating NOTCH2 
mutations were detected in 4/5 (80%) dural MZL displaying variable monocytoid 
morphology. Inactivating TBL1XR1 mutations were identified in all NOTCH2 mutated 
cases. Recurrent mutations in KLHL6 (n=2) and MLL2 (n=2) were also detected. Gains 
at 6p25.3 (n=2) and losses at 1p36.32 (n=3) were common chromosomal imbalances, 
with loss of heterozygosity (LOH) of these loci observed in a subset of cases. 
Translocations involving the IGH or MALT1 genes were not identified. Our results 
indicate genetic similarities between dural MZL and other MZL subtypes. However, 
recurrent and mutually exclusive genetic alterations of TNFAIP3 and NOTCH2 appear 
to be associated with distinct disease phenotypes in dural MZL.
IntroductIon
Diffuse large B-cell lymphoma is the most common 
subtype of B-cell non-Hodgkin lymphoma (B-NHL) 
occurring in the central nervous system (CNS) [1]. In 
contrast, the meninges are the most common primary 
(or secondary) site of involvement by low grade B-NHL 
[2]. The dura is a recognized but uncommon, primary 
site of occurrence of marginal zone lymphoma (MZL) 
and rare cases of intra-parenchymal MZLs, occurring 
in a perivascular location, have also been described [3, 
4]. A female predilection has been documented for dural 
MZLs, and since they often present as solitary masses, 
they can mimic meningioma’s clinically and on imaging 
studies [5-7]. Most patients are cured following excision 
and local adjuvant therapy but systemic recurrences 
have occasionally been reported [8]. Based on their 
morphologic and phenotypic features, primary dural 
MZLs are considered similar to mucosa-associated 
lymphoid tissue (MALT) lymphomas [5, 9]. Intriguingly, 
a high proportion of dural MZLs (up to 47%) show a 
prominent, light chain-restricted plasmacytic component, 
with a subset displaying clonal IgG4+ plasma cells in the 
absence of an IgG4-related disorder [6, 7].
Data regarding the chromosomal aberrations 
underlying dural MZLs are limited. Trisomy 3 has been 
reported as a recurrent cytogenetic abnormality in up 
to 50% of cases [6, 7]. The genomic and mutational 
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landscape of dural MZLs, however, remains unexplored 
and the relationship of dural MZL with other MZL 
subtypes has not been defined [10-12]. In this report, we 
describe the results of genome-wide DNA copy number 
and targeted mutational analyses of 14 dural MZL. We 
detected recurrent and apparently mutually exclusive 
alterations in two genes critical for normal marginal zone 
B-cell development and maintenance or homeostasis, 
NOTCH2 and TNFAIP3, which appear to be associated 
with distinct disease phenotypes, as well as a variety of 
additional genomic aberrations in common with other 
MZL subtypes. 
results And dIscussIon
All fourteen patients were adults (age range 
33-62, median 46.5) and there was a marked female 
predominance (12 females, 2 males). None had a prior 
history of any hematological malignancy. Imaging studies 
showed solitary dural-based mass lesions (13 cranial, 1 
spinal). All patients underwent surgical resection and 8/14 
(57%) also received radiation (n=5) and/or chemotherapy 
(n=4). Ten of 11 (90%) patients with follow up data are 
alive and disease-free (follow up 12-120 months, median 
29 months) and 1 patient died of a disease-unrelated cause 
(Table 1). 
Five cases exhibited variable monocytoid 
cytomorphology and nine cases showed extensive 
table 1: clinical features of dural MZl patients














Left jaw numbness, 
left-sided auditory 
defects





Cranial Dura Solitary mass RTX Alive- NED 26





5 45 F Back pain and spasms Spinal Dura Solitary mass N/A
Alive- 
NED 120
6 42 F Headaches Cranial Dura Solitary mass RTX Alive- NED 29
7 60 F N/A Cranial Dura Solitary mass RTX Alive- NED 22
8 34 F Seizures Cranial Dura Solitary mass CTX Alive- NED 12
9 62 F Headaches, right-sided numbness Cranial Dura Solitary mass CTX
Alive-
NED N/A
10 50 F N/A Cranial Dura Solitary mass N/A N/A N/A





Cranial Dura Solitary mass RTX Alive-NED 108
13 42 F Seizures Cranial Dura Solitary mass N/A N/A N/A
14 37 M N/A Cranial Dura Solitary mass N/A N/A N/A
F: female; M: male; N/A: not available; RTX: radiation therapy; CTX: chemotherapy; NED: no evidence of disease
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plasmacytic differentiation, with 6/9 cases (67%) 
displaying clonal IgG4+ plasma cells (Figure 1, 
Table 2). None of the latter had a history of sclerosing 
pachymeningitis (meningeal IgG4-related disease) or 
systemic IgG4-related disease before or after the diagnosis 
of lymphoma, supporting the notion that a subset of 
MZL represent localized and de novo IgG4-positive 
lymphoproliferations [7, 13]. 
G-band chromosome analysis showed normal 
karyotypes in 4 cases and it failed in 3 cases. Interphase 
FISH analysis using IGH, MALT1 and BCL6 probes 
showed no rearrangements but an additional copy of 
MALT1 was noted as a subclonal change in one MZL (case 
1). PCR analysis for immunoglobulin heavy chain (IGH) 
gene rearrangement showed clonal products in 12/13 
(92%) evaluable cases (Table 2). 
Targeted next generation sequencing analysis of 465 
cancer-associated genes (Supplementary Table 1), with an 
average of 684-fold coverage and >10X coverage for 99% 
of the coding regions (Supplementary Table 2), revealed 
somatic mutations in all 11 cases (100%) with informative 
results; sequencing failed in 3 MZLs (cases 12-14).
Sequencing and whole genome DNA copy number 
analysis showed inactivation of TNFAIP3 in 6/9 (67%) 
cases exhibiting plasmacytic differentiation (Figure 
2, Table 3). Loss of function mutations of TNFAIP3 
were identified in 5/9 (56%) cases, including two novel 
variants (Supplementary Table 3). Concomitant loss 
table 2: Histopathologic, cytogenetic and molecular features of dural MZL
case no Plasma cells cd20 cd79a
MuM1/
IrF4 cd138 K/l IgG4 Ki-67 Karyotype FIsH IGH Pcr
1 - + + - - Poly - 5-10% N/A
IGH=NR, 
3 copies of 
MALT1
Clonal
2 - + + ± - Poly - 5-10% N/A IGH=NR, MALT1=NR Clonal










5 - + N/A N/A N/A Poly - N/A Failure IGH=NR, MALT1=NR Polyclonal





7 + + + + + K + 10-20% N/A MALT1=NR Clonal










10 + + + + N/A K + 20-50% N/A BCL6=NR Clonal















14 + + N/A ± N/A K - 5-10% Normal BCL6=NR Clonal
N/A: not available; Poly: polytypic; K: kappa light chain restriction; L: lambda light chain restriction; NR: not rearranged
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Figure 1: Morphologic and immunophenotypic features of dural MZl. A. Dense, vaguely nodular lymphocytic infiltrate 
composed of atypical, small lymphocytes exhibiting irregular nuclei, fine chromatin, indistinct nucleoli and abundant pale cytoplasm 
(monocytoid appearance). The cells are positive for CD20, BCL2, MUM1/IRF4(weak), negative for CD138 and have a low proliferation 
index (Ki-67 <5%). CD138 shows rare plasma cells. CD21 shows disrupted follicular dendritic cell meshworks. b. Dense vaguely nodular 
lymphocytic and plasmacytic infiltrate composed of small lymphocytes, some exhibiting plasmacytoid features, and plasma cells. The 
lymphocytes express CD20, while the  plasma cells express CD138 and MUM1/IRF4(bright) and they show kappa light chain restriction 
and IgG4 expression. CD21 shows rare, small and fragmented follicular dendritic cell meshworks. Ki-67 staining shows a low proliferation 
index (<10%).
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Table 3: Genetic abnormalities in the two morphologic variants of dural MZL
Figure 2: summary ideogram showing genomic alterations in dural MZl. Blue indicates gains, red indicates losses and green 
indicates loss of heterozygosity (LOH).
 Columns represent individual cases and the rows represent genes (two rows for each gene represent the two alleles). PC: plasmacytic differentiation
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of heterozygosity (LOH) at 6q23 was noted in 2 cases, 
indicating bi-allelic TNFAIP3 inactivation. Additionally, 
loss of 6q23 involving the TNFAIP3 locus and LOH in 
this region were seen in one case each (1/9, 11%); poor 
DNA quality precluded assessment of mutations in these 
cases (Supplementary Table 4). 
TNFAIP3 (also known as A20) is a negative 
regulator of NF-κB signaling [14, 15]. B-cell specific 
deletion of TNFAIP3 in mice results in mislocalization 
of marginal zone B-cells and defective antigen-induced 
B-cell maturation [16]. TNFAIP3-deficient B-cells are 
hyper-reactive to antigen stimulation, leading to enhanced 
proliferation and survival. Mice with B-cells lacking 
TNFAIP3 also demonstrate plasma cell hyperplasia and 
chronic inflammation, and they develop autoimmune 
disorders upon aging [16]. Recurrent inactivating 
mutations and/or genomic loss of TNFAIP3 have been 
described in Hodgkin and non-Hodgkin lymphomas, 
including diffuse large B-cell lymphoma (DLBCL) 
[17, 18], extranodal MZL and nodal MZL [10, 11, 19]. 
However, an association with plasmacytic differentiation 
has not been reported for any type of B-NHL harboring 
this genetic alteration. 
Activating NOTCH2 mutations were identified in 
4/5 (80%) cases manifesting variable monocytoid features, 
including three novel variants (Table 3, Supplementary 
Table 3). Bi-allelic NOTCH2 aberrations were identified 
in two cases; bi-allelic mutations in one and a mutation 
accompanied by LOH at 1p11, containing the NOTCH2 
locus, in another. NOTCH2 mutations were either located 
in the transactivation domain (TAD) or the proline/
glutamate/serine/threonine-rich (PEST) domain, resulting 
in deletion of protein degradation motifs that regulate 
protein stability [20].
NOTCH2 is indispensable for marginal zone B-cell 
development and maintenance [21]. Targeted deletion 
of NOTCH2 in murine B-cells results in the complete 
absence of marginal zone B-cells and their precursors i.e. 
transitional T2 B-cells [22]. Conversely, constitutively 
active NOTCH2 signaling in murine B-cells leads to 
an expansion of marginal zone B-cells at the expense 
of follicular B-cells. However, mice with constitutive 
NOTCH2 expression do not develop B-cell lymphoma, 
suggesting that sustained NOTCH2 signaling alone 
is insufficient for B-cell lymphomagenesis [23]. The 
majority of documented NOTCH2 mutations in B-NHLs 
target the C-terminal transactivation (TAD) domain or the 
proline/glutamate/serine/threonine-rich (PEST) domain, 
resulting in increased protein stability and uncontrolled 
activation of the NOTCH2 and NF-κB pathways [24]. 
NOTCH2 activating mutations have been identified in a 
variety of lymphomas, including splenic MZL, follicular 
lymphoma (FL) and DLBCL, and their presence is thought 
to predict an aggressive clinical course in certain B-NHLs 
[24-28]. Until now, NOTCH2 mutations have not been 
described in non-splenic MZL. 
Of note, recurrent TBL1XR1 mutations (4/11, 36%) 
were only seen in association with NOTCH2 mutations 
(Table 3, Supplementary Table 3), which could indicate a 
co-operative role for these mutations in lymphomagenesis. 
TBL1XR1 is a transcriptional regulator of the Wnt/β-
catenin and NF-κB pathways and recurrent mutations of 
Figure 3: Sanger confirmation of NOTCH2 and TNFAIP3 mutations.
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this gene have previously been described in other subtypes 
of B-NHL, especially splenic MZL and primary CNS 
DLBCL [28, 29]. Other recurrently mutated genes in dural 
MZL included KLHL6 (2/11, 18%) and MLL2/KMT2D 
(2/11, 18%) (Table 3). A role in B-cell receptor signaling 
has been proposed for KLHL6 and recurrent KLHL6 
mutations have been described in chronic lymphocytic 
leukemia [30]. MLL2/KMT2D plays an important role 
in chromatin remodeling and transcriptional regulation 
and loss of function MLL2/KMT2D mutations have 
been described in a variety of B-NHL, including splenic 
MZL [28, 31, 32]. Non-recurrent mutations of CARD11, 
RHOA, MLL/KMT2A, TNFRSF14, and PTPRC were 
also identified and the variant allele frequencies of some 
mutations suggested that they might represent secondary 
events (Supplementary Table 3). 
The recurrent mutations described above were 
confirmed by Sanger sequencing (Supplementary Table 3, 
representative examples are shown in Figure 3).
Whole genome DNA copy number analysis showed 
chromosomal alterations in 12 of 13 cases (median - 4 per 
case, range 1-9), including recurrent aberrations involving 
1p36.32 [loss, 3/13 (23%), LOH, 3/13 (23%)], with the 
minimal common region of aberration encompassing 
TNFRSF14, PRDM16, RPL22 and CAMTA1 genes, and 
6p25.3 [gain, 2/13 (15%), LOH, 1/13 (8%)], encompassing 
the IRF4 gene. Whole chromosome abnormalities were 
identified in 2/13 (15%) cases, including one case that 
showed gains of 3 and 18 (Figure 2, Supplementary Table 
4), which were not observed by FISH analysis, potentially 
representing subclonal changes. The observed genomic 
changes are similar to those described previously in other 
MZL subtypes, although the frequencies appear to differ 
[10, 11]. Importantly, our findings suggest that in contrast 
to other MZL subtypes, aberrations of chromosomes 3 and 
18 are infrequent in primary dural MZL [6, 7]. 
In summary, we report recurrent and apparently 
mutually exclusive genetic alterations of TNFAIP3 
and NOTCH2 in dural MZL, in addition to novel and 
previously described mutations and genomic aberrations 
associated with other MZL subtypes. Contrary to 
observations in other B-NHL, these genetic aberrations 
do not appear to portend an aggressive course in dural 
MZL. Until now, specific genotype-phenotype correlations 
have not been reported for other MZL subtypes and our 
findings raise the possibility of at least two independent 
pathways leading to dysregulated NF-κB signaling in 
dural MZL that our associated with distinct disease 
phenotypes. However, larger studies with longer follow 
up are warranted to clarify the prognostic implications and 




Fourteen primary dural MZL cases with adequate 
formalin-fixed paraffin-embedded (FFPE) tissue (>50% 
tumor) were identified in the archives of the Departments 
of Pathology, Columbia University Medical Center, New 
York (n=9) and the National Cancer Institute, Bethesda, 
Maryland (n=5). The latter were part of a previously 
published series [7]. Clinical, radiological and treatment 
data were reviewed for all cases. The study was performed 
using protocols approved by the institutional review 
boards of both institutions and in accordance with the 
principles of the Declaration of Helsinki. 
Morphologic and immunophenotypic evaluation
Hematoxylin and Eosin (H&E) stained FFPE 
tissue sections were reviewed to assess cyto-architectural 
features. Immunohistochemistry and in-situ hybridization 
was performed with the following panel of antibodies 
and probes; CD20 (clone MJ1); CD10 (clone 56C6); 
CD5 (clone 4C7); BCL6 (clone LN22); BCL2 (clone 
D5); CD21 (clone PA0171); kappa (clone ISH-5748A), 
lambda (clone ISH-5770A), all from Leica, IL, USA; 
CD79a (clone AP18); Cyclin D1 (clone SP4-R); CD138 
(clone B-A38); CD21 (clone PA0171); IgG (clone 
1210208A); IgG4 (clone 1123107A); Ki-67 (clone 30-9), 
all from Ventana, AZ, USA; and MUM-1 (clone MUM1p) 
from DAKO, CA, USA. Staining was performed with 
automated stainers (Ventana Benchmark Ultra and Leica 
Bond III) and visualized with the UltraView Universal 
and Bond polymer DAB detection kits according to the 
manufacturer’s protocols. 
cytogenetic analysis 
Giemsa (G) banding and karyotype analysis was 
performed on metaphase preparations from fresh tumor 
specimens (n=7) after short-term (24 hr.) culture using 
standard techniques and karyotypes were described 
according to the International System for Human 
Cytogenetic Nomenclature [33].
Fluorescence in situ hybridization (FISH) analysis 
using IGH (n=11), MALT1 (n=12) and BCL6 (n=10) 
break-apart probes (Abbott Laboratories, Abbott Park, 
Illinois, USA) was performed on FFPE tissue sections. 
FISH signals were scored on 200-500 interphase nuclei 
after counterstaining with DAPI using a Nikon Eclipse 
600 microscope and captured with the Cytovision Imaging 
system (Applied Imaging, Santa Clara, CA). 
Oncotarget43059www.impactjournals.com/oncotarget
Immunoglobulin heavy chain (IGH) gene 
rearrangement analysis
DNA was extracted from FFPE tissue and 
fluorescent polymerase chain reaction (PCR) was 
performed using the BIOMED-2 primers, followed by 
capillary gel electrophoresis, to ascertain the presence of 
clonal IGH gene rearrangements, as described [34].
next generation sequencing
Targeted next generation sequencing was successful 
in 11 of 14 cases using a panel comprising 465 cancer-
associated genes (Supplementary Table 1). Fifty to 250 ng 
of DNA, extracted using the Qiamp mini kit or the Qiamp 
FFPE kit (Qiagen, Germantown, USA) was fragmented 
to a median of 150-200bp, by sonication. Following end-
repair and 3’ adenylation of the fragments, and ligation of 
double-stranded sequencing and indexing adaptors to ends, 
target capture and enrichment was performed with the 
Sure Select Hybrid Capture system (Agilent Technologies, 
Santa Clara, USA), using custom designed probes. 
Libraries were then quantified using qPCR, diluted to 2nM 
and pooled, prior to cluster generation and analysis on 
Illumina HiSeq2500, using Illumina TruSeq v3 chemistry 
(San Diego, USA) and 100bp paired-end reads (up to 9 
indexed samples per run). Fastq files of reads where over 
70% of reads were above Q30, were demultiplexed with 
CASAVA, and samples with at least 6Gb of data were used 
for mapping and variant calling using NextGene Software 
(Softgenetics, State College, USA), using the following 
criteria: 0 allowable ambiguous alignments, at least 90% 
of a read having to match the reference genome, software 
set to detect large indels, hiding the unmatched ends of 
reads, with at least 10% variant allelic fraction, and at least 
3 variant reads to call a variant.
After annotation, the variants were cross referenced 
with those in the 1000 Genomes Project, OMIM, dbSNP, 
and the Exome Variant Server. Variants with an allele 
prevalence >1% in the 1000 genomes project were 
excluded. Common variants present in our departmental 
database of variants identified in prior constitutional 
exome analysis, non-pathogenic variants reported in 
dbSNP, and low quality calls were filtered out. The 
remaining variants were submitted for manual curation 
and variant prioritization with visual review of alignments. 
Synonymous variants and intronic variants greater than 2 
bp from the coding sequence were excluded. Variants were 
manually cross-referenced with the Catalog of Somatic 
Variants in Cancer (COSMIC) and those that were not 
known “hot spot” mutations or had not been previously 
reported as potential driver variants were analyzed by 
PROVEAN and SIFT algorithms (Supplementary Table 
2). Matched normal tissue samples (bone marrow aspirate) 
were available for two MZLs (cases 4 and 9). Variants 
present in the normal sample were excluded from analysis 
in these cases.
Whole genome copy number and loss of 
heterozygosity (loH) analysis
Genome-wide DNA copy number and LOH analysis 
was performed in 13 of 14 cases using the Affymetrix 
OncoScan FFPE assay (Affymetrix, CA, USA), which 
utilizes molecular inversion probe technology and is 
optimized to work on DNA derived from FFPE tissue 
samples [35].
Sample preparation, hybridization and scanning 
were performed according to the manufacturer’s 
specifications. Analysis was performed using the 
Affymetrix Chromosome Analysis Suite 2.0 (ChAS) and 
Nexus Copy Number 7.5 software (Biodiscovery, Inc. 
CA, USA). All copy number alterations and regions of 
LOH recognized by the software were verified visually 
to determine erroneous calls and identify clonal or 
subclonal gains and losses not detected by the software. 
Analysis was restricted to gains and losses >1 Mb in 
length (Supplementary Table 4). Genomic alterations were 
reported based on the NCBI build 37 (hg19) of the human 
genome and cancer-associated genes were curated from 
the Cancer Gene Census (COSMIC v61 Release; http://
www.sanger.ac.uk/genetics/CGP/Census/)
sanger sequencing
Recurrent mutations deemed to be pathogenic were 
confirmed by Sanger sequencing according to standard 
methods. Briefly, PCR products obtained with specific 
primers flanking the mutation of interest were treated with 
exonuclease and shrimp alkaline phosphatase to remove 
remaining primers and dNTPs, and used as substrates for 
cycle sequencing using the BidDye Terminator Version 
3.1 chemistry (Thermo Fisher, Springfield Township, 
USA), analyzed on an ABI 3130XL capillary sequencer 
(ThermoFisher, USA), and evaluated using Mutation 
Surveyor (Softgenetics, State College, USA).
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